Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis

  title={Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis},
  author={Ana Julissa Serrano and Leire Bego{\~n}a and Eduardo Anitua and Raquel Victoria Jara Cobos and Gorka Orive},
  journal={Gynecological Endocrinology},
  pages={1005 - 1014}
Abstract The aim of this meta-analysis was to evaluate the efficacy and safety of two bisphosphonates (alendronate and zoledronate) in the treatment of postmenopausal osteoporosis. The incidence of fractures was considered as primary endpoint. Only randomized trials with a follow-up period of 1 year or more were included in this systematic review and meta-analysis. We excluded studies that included patients with secondary osteoporosis especially in relation to therapy with corticosteroids or… 

Efficacy of Bisphosphonates for Preventing Osteoporotic Fracture in Postmenopausal Women: A Systematic Review and Meta – Analysis

Bisphosphonates were efficacious in preventing bone fractures in postmenopausal women with osteoporosis, however, studies on clodronate, etidronate and ibandronate were limited, thus further studies should be conducted.

The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment

This study suggests that, taking efficacy and safety into account, parathyroid hormone and zoledronic acid had the highest probability of satisfactory performance in preventing osteoporotic fractures.

The Safety of Bisphosphonates for Primary Osteoporosis: An Overview of Systematic Reviews and Meta-analysis

An overview of systematic reviews to evaluate the risk of adverse events of BPs used in primary osteoporosis and a new meta-analysis for the primary outcomes as the conflicting results of the original systematic reviews are made.

Safety of Bisphosphonates for Postmenopausal osteoporosis: An Overview of Systematic Reviews

An overview of reviews to systematically evaluate the risk of adverse events (AEs) of bisphosphonates used for the treatment of postmenopausal osteoporosis indicated that bisph phosphonates significantly increased therisk of AF, sAF and stroke, but did not significantly increase the riskof atypical fracture or fracture union.

Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease

The result showed that bisphosphonates decreased bone mass density (BMD) loss at the lumbar spine, reduced the risk of new fractures, and retained the similar adverse events in patients with IBD.

Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis

Zoledronate might be the best choice to increase the BMD in LS and teriparatide (20mg) might lead to the lowest fracture rate.

Design of the SALT Osteoporosis Study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older

The design of the SALT Osteoporosis study, which aims to examine whether the screening and treatment of older, female patients in primary care can reduce fractures, in comparison to usual care, is described.

Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control

Combining both adjusted direct comparisons and own-control analysis may provide an estimate of real-world treatment efficacy that could potentially complement clinical trial findings.

A Comparative Study of the Effect of Sodium Alendronate plus Thyme and Sodium Alendronate alone in Treatment of Postmenopausal Women with Osteoporosis

Assessment of the efficacy of sodium alendronate plus Thyme in treatment of postmenopausal women with osteoporosis found a significant increase in BMD and significant rise in t score in group treated with Sodium alendronsateplus Thyme after 6 months as compared with baseline.



Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.

Alendronate increases bone density in both early postmenopausal women and those with established osteoporosis while reducing the rate of vertebral fracture over 2-3 yr of treatment, casting doubt on traditional distinctions between osteopootic and nonosteoporotic fractures.

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

Therapy with alendronate is associated with significant and clinically important reductions in the incidence of hip fracture in women with postmenopausal osteoporosis, and the overall reduction is consistent among different patient populations.

A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group.

The present results indicate that alendronate effectively decreases bone turnover in a dose-related manner and increases lumbar BMD at a dosage of 2.5 mg/day, the lowest dose used in this study, in Japanese patients with osteoporosis.

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

At 10 mg per day, both clinically important and statistically significant reductions in vertebral, non-vertebral, hip and wrist fractures were observed for secondary prevention andgold' level evidence, was found.

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Etidronate, at 400 mg per day, demonstrated a statistically significant and clinically important benefit in the secondary prevention of vertebral fractures in postmenopausal women.

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

For postmenopausal women with low bone mass, alendronate is well tolerated and produces significant, progressive increases in BMD at the lumbar spine and hip in addition to significant reduction in the risk of nonvertebral fracture.

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.

It is concluded that treatment with ALN over a period of 2 yr was well tolerated and produced dose-dependent increases in BMD without evidence of a plateau over the dose range of 1.0-5.0 mg daily.

Zoledronic acid and clinical fractures and mortality after hip fracture.

An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival.